Oncobiologics Warrants Series A Exp 18 Feb 2019 (ONSIW)

  • Get an in-depth profile of Oncobiologics Warrants Series A Exp 18 Feb 2019, including a general overview of the company's business and key management, as well as employee data and location and contact information.
0.15 +0.00 (+0.00%)
Real-time Cboe USD Disclaimer

Oncobiologics Warrants Series A Exp 18 Feb 2019 Company Profile

Industry
Biotechnology & Medical Research
Sector
Healthcare
Employees
9
Equity Type
Warrant
Outlook Therapeutics, Inc., a late clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration and license agreements with IPCA Laboratories Limited; Laboratorios Liomont, S.A. de C.V.; BioLexis Pte. Ltd.; and Zhejiang Huahai Pharmaceutical Co., Ltd. The company was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018. Outlook Therapeutics, Inc. was incorporated in 2010 and is based in Iselin, New Jersey.
Contact Information
Address
485 Route 1 South Iselin,08852 United States
Phone
609 619 3990
Fax
-
Web
https://www.outlooktherapeutics.com

Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.